



News Release

HYDERABAD, INDIA (11 Aug' 2020) -- SUVEN Life Sciences Limited ("Suven", "Company") today announced unaudited financial results for the quarter ended 30th June 2020. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 11 Aug' 2020 at Hyderabad.

CONDENSED STATEMENT OF OPERATIONS

INR Lakhs

	Standalone		Consolidated			
	Jun-20	Mar-20	Jun-19	Jun-20	Mar-20	Jun-19
Revenue	395.79	1,165.71	439.78	395.79	1,165.71	439.78
R&D and Operational expenses	921.83	1,073.74	1,291.49	1,562.52	3,373.19	4,348.93
Depreciation and Amortisation	106.49	105.24	84.52	106.49	105.24	84.52
Finance cost	21.93	23.21	10.61	22.43	23.23	10.90
Total expenses	1,050.25	1,202.19	1,386.62	1,691.44	3,501.66	4,444.35
Tax	(246.72)	219.87	(1,401.27)	(246.72)	219.87	(1,401.27)
Profit/(Loss) After Tax for the period/year	(407.74)	(256.35)	454.43	(1,048.93)	(2,555.82)	(2,603.30)
Other comprehensive income	(7.38)	(18.79)	(0.69)	(7.38)	(18.79)	(0.69)
Total comprehensive income	(415.12)	(275.14)	453.74	(1,056.31)	(2,574.61)	(2,603.99)
Paid up equity capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
Earnings per share of Rs.1 each (EPS)	(0.32)	(0.20)	0.36	(0.82)	(2.01)	(2.05)

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) Consolidated statement includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) Based on promising results in sub-group analysis of molecule SUVN-502, masupirdine for some of the secondary endpoints, Suven is in discussion with Key Opinion Leaders (KOLs) in US to finalize the protocol for Phase 2 POC study for the treatment of Behavioral and psychological symptoms of dementia (BPSD).
- (d) Ongoing phase 2 study in USA on SUVN-G3031, targeted against Narcolepsy (excessive day time sleep disorder) is progressing well and expected to reach interim analysis stage of completing 50% of patients' enrollment soon.
- (e) Since last reporting period, the Company has been granted 15 patents for its innovative drug discovery covering ARIPO, Australia, Canada, China, Europe, Israel, Japan, Macau, South Africa and South Korea.
- (f) The Board has approved the offering of ESOPs not exceeding 10,00,000 options, subject to approval of members in General meeting.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive;

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com